Celltrion Archives | Page 4 of 7

Home / Posts tagged Celltrion (Page 4)

Celltrion Begins Developing COVID-19 Cocktail Treatment to Tackle Variants

SEOUL, Feb. 18 (Korea Bizwire) – Celltrion Inc. said Thursday that its anti-COVID-19 monoclonal antibody treatment has confirmed neutralizing potency against the British variant, and the South Korean pharmaceutical giant has also begun developing a neutralizing antibody cocktail treatment. CT-P59, an anti-COVID-19 monoclonal antibody treatment, won the country’s drug safety agency’s conditional approval earlier this [...]

Celltrion Begins Supplying COVID-19 Antibody Treatment

SEOUL, Feb. 17 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. began supplying its COVID-19 antibody treatment to medical institutions in the country Wednesday. CT-P59 won the drug safety agency’s conditional approval earlier this month, becoming the first locally made treatment for COVID-19. CT-P59 will be administered to COVID-19 patients at higher risk, referring [...]

S. Korea OKs Celltrion’s COVID-19 Treatment for Conditional Use

SEOUL, Feb. 5 (Korea Bizwire) — South Korea’s drug safety agency said Friday it has approved pharmaceutical giant Celltrion Inc.’s COVID-19 treatment candidate on several conditions. The conditional marketing authorization of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, marks the country’s first homegrown COVID-19 treatment. The Korean Ministry of Food and Drug Safety said CT-P59 [...]

Celltrion Says its COVID-19 Treatment Cuts Recovery Time, Chance of Severe Cases

SEOUL, Jan. 13 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Wednesday that its COVID-19 treatment candidate reduces recovery time and the chance of a severe case developing. It was making public clinical data on the second-phase global trial study of the CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate. The firm earlier submitted [...]

Celltrion’s COVID-19 Treatment Shows Higher Efficacy than 2 Rivals

SEOUL, Jan. 12 (Korea Bizwire) — South Korea’s pharmaceutical giant Celltrion Inc. said Tuesday that its anti-COVID-19 monoclonal antibody treatment has shown higher treatment efficacy compared to its two rival candidates. The Korean Ministry of Food and Drug Safety is currently reviewing conditional approval of Celltrion’s CT-P59, also known as Regdanvimab, a move that could [...]

Celltrion Inks Supply Agreement for COVID-19 Test Kit in U.S.

SEOUL, Dec. 18 (Korea Bizwire) — South Korean biopharmaceutical giant Celltrion Inc. said Friday it has signed an agreement worth 240 billion won (US$220 million) to supply a diagnostic kit for the novel coronavirus in the United States. Under the agreement, Celltrion’s rapid antibody diagnostic test (RDT) kit for the new coronavirus, named DiaTrust, will [...]

Celltrion Eyes Emergency Authorization for COVID-19 Treatment Next Month

SEOUL, Nov. 18 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc.’s coronavirus treatment is likely to file for emergency authorization use from local drug authorities next month, the company’s chief said Wednesday. CT-P59, anti-COVID-19 monoclonal antibody treatment, is currently undergoing a phase two clinical trial locally after successfully completing a phase one clinical trial [...]

Celltrion to Spend 500 bln Won for 3rd Plant amid Growing Demand

SEOUL, Nov. 18 (Korea Bizwire) — Celltrion Inc., a leading pharmaceutical firm in South Korea, said Wednesday that it will build a third plant in the country in response to rising manufacturing demand. The 500 billion-won (US$452 million) plant in the country’s biotech hub of Songdo, west of Seoul, will have a bioreactor capacity of [...]

Celltrion’s COVID-19 Treatment Kills Virus Within 4-5 Days: Chief

SEOUL, Nov. 11 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc.’s COVID-19 treatment kills the coronavirus within 4-5 days, effectively protecting patients with mild symptoms from developing a severe case, the company’s chief said Wednesday. Celltrion Group Chairman Seo Jung-jin said the first stage trial of CT-P59, anti-COVID-19 monoclonal antibody treatment, shortened the recovery [...]

Celltrion Q3 Net Profit Nearly Triples on Robust Overseas Sales

SEOUL, Nov. 9 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Monday that its net profit jumped 185.4 percent on-year in the third quarter on the back of robust sales of its products in overseas markets. Net profit came to 175.8 billion won (US$157.8 million) during the July-Sept. period on a [...]